PLB1004, wanda Beijing Avistone Biotechnology Co., Ltd. ta ƙirƙiro, wani magani ne mai aminci, mai zaɓe sosai, kuma mai inganci wanda ba za a iya canza shi ba, wanda ake amfani da shi wajen magance cutar kansar huhu (NSCLC) wadda ba ta da ƙaramin ƙwayar halitta.
A ranar 9 ga Afrilu, 2025, Cibiyar Kimanta Magunguna ta Hukumar Kula da Kayayyakin Lafiya ta Ƙasa (CDE) ta nuna cewa an yi niyyar haɗa PLB1004 na Beijing Avistone Biotechnology a cikin maganin da aka yi wa marasa lafiya da suka kamu da cutar kansar huhu ta METastatic (NSCLC) waɗanda suka kamu da cutar EGFR, suka gamu da ƙaruwar yawan magana da/ko yawan magana bayan gazawar maganin EGFR-TKI.
An sanar da sakamakon farko na asibiti na PLB1004 tare da Vebreltinib a cikin maganin marasa lafiya da ke fama da cutar kansar huhu marasa ƙanana waɗanda ke da maye gurbi na EGFR, ƙara yawan MET ko yawan bayyanar MET bayan EGFR-TKI a taron duniya kan cutar kansar huhu na 2024.
Marasa lafiya arba'in da huɗu sun karɓi Vebreltinib 100mg tare da PLB1004 160mg (n=15), Vebreltinib 150mg tare da PLB1004 160mg (n=13), Vebreltinib 200mg tare da PLB1004 80mg (n=3), ko Vebreltinib 150mg tare da PLB1004 80mg (n=13) kuma an haɗa su cikin nazarin aminci gabaɗaya. Daga cikin marasa lafiya 44 da aka tantance, kashi 36.4% na marasa lafiya sun sami ciwon kwakwalwa kuma kashi 86.4% na marasa lafiya sun taɓa samun ciwon EGFR-TKI na ƙarni na uku, bi da bi. An sami amsoshi masu ma'ana a duk matakan allurar Vebreltinib da PLB1004 da aka gwada, tare da lura da amsoshi na ɓangare (PRs) a cikin marasa lafiya da za a iya kimanta amsawar su a 19/32 (59.4%). Daga cikin marasa lafiya da suka sami ciwon kwakwalwa, ORR shine kashi 75.0% (9/12). ORR ya kasance kashi 58.6% (17/29) a cikin marasa lafiya da suka taɓa shan EGFR-TKI na ƙarni na uku. Mafi yawan cututtukan TRAE sune kurji da paronychia. Babu wani majiyyaci da ya daina shan magani saboda TRAEs.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Lokacin Saƙo: Afrilu-10-2025